Online inquiry

IVTScrip™ mRNA-Anti-RABVgp4, CR57(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ6233MR)

This product GTTS-WQ6233MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets RABVgp4 gene. The antibody can be applied in Rabies research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NP_056796.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 1489856
UniProt ID P08667
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-RABVgp4, CR57(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ6233MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ1744MR IVTScrip™ mRNA-Anti-IL2RA, ADCT-301(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA ADCT-301
GTTS-WQ8247MR IVTScrip™ mRNA-Anti-PDCD1, HLX10(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA HLX10
GTTS-WQ3470MR IVTScrip™ mRNA-Anti-pcrV, BA1126(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA BA1126
GTTS-WQ4787MR IVTScrip™ mRNA-Anti-DPP4, BT 5/9(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA BT 5/9
GTTS-WQ10214MR IVTScrip™ mRNA-Anti-RHD, LFB-R593(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA LFB-R593
GTTS-WQ10453MR IVTScrip™ mRNA-Anti-SOST, LY2541546(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA LY2541546
GTTS-WQ8935MR IVTScrip™ mRNA-Anti-IL1B, IL-1 Trap(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA IL-1 Trap
GTTS-WQ12172MR IVTScrip™ mRNA-Anti-MSLN, MORAb-009(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA MORAb-009
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW